跳至主要内容
临床试验/NCT00602134
NCT00602134已完成不适用

A Pharmacokinetic Study to Assess the Single-Dose Bioequivalence of a Potential Generic Formulation of a 6-Mercaptopurine 50 mg Tablet Compared to a Marketed 6-Mercaptopurine 50 mg Tablet, Purinethol®, When Administered to Healthy Male Subjects, in the Fasted State

Roxane Laboratories2 个研究点 分布在 1 个国家目标入组 54 人开始时间: 2002年11月最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
54
试验地点
2
主要终点
Bioequivalence

研究概览

简要总结

The objective of this study was to assess the bioequivalence of a potential generic 6-mercaptopurine 50 mg tablet formulation compared with GlaxoSmithKline Purinethol® (mercaptopurine) 50-mg scored tablets following a single 50 mg oral dose administered in the fasted state.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • No clinically significant abnormal findings on physical examination, medical history, or clinical laboratory results.
  • Must voluntarily consent.

排除标准

  • Must not have a known history of thiopurine methyltransferase deficiency or family history.
  • Must not have a history of elevated uric acid or gout.
  • Must not be currently using allopurinol.

结局指标

主要结局

Bioequivalence

时间窗: Baseline, two period, 3 day washout

次要结局

未报告次要终点

研究者

申办方类型
Industry

研究点 (2)

Loading locations...

相似试验